Menu

奥拉迪约不良反应及奥拉迪约注意事项

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Oradejo is the first targeted oral therapy approved to prevent HAE attacks. The approval of this drug will bring significant progress in the treatment of HAE patients and help reduce the treatment burden on patients. On December 3, 2020, BioCryst announced that its once-daily oral beroxostat capsule Orladeyo was approved by the US FDA for marketing. Today, let’s learn about Orladeyo’s adverse reactions and Orladeyo precautions.

The following side effects may occur when taking Orladi for dating:

1. Heart rhythm problems. Taking more than one Orladeyo capsule a day may cause heart rhythm problems with QT prolongation, a condition that causes an abnormal heartbeat.

2. The most common adverse reactions (≥10%) of Oradejo are abdominal pain, vomiting, diarrhea, back pain and gastroesophageal reflux disease.

3. Less common side effects of Oradejo include: abnormal liver function indicators.

4. Rare side effects: transient, itchy rash.

But you need to pay attention to the following when taking Oradejo:

1. Risk of QT prolongation at higher than recommended doses: Orladeyo should not be used to treat acute attacks of HAE. Additional once daily doses or doses above 150 mg of Orladeyo are not recommended. A concentration-dependent increase in QT was observed at doses above the recommended daily dose of 150 mg.

2. Drug Interactions: Inform patients that Orladeyo may interact with other drugs. Advise patients to report the use of any other prescription or over-the-counter medications or herbal products to their physician.

3. Not suitable for acute treatment of acute ischemic encephalopathy attacks: It is recommended that patients take commonly used rescue drugs to treat acute ischemic encephalopathy attacks. Inform patients that the safety and effectiveness of using Orladeyo as an acute treatment for HAE attacks have not been established. Advise patients not to take daily doses greater than 150 mg or additional doses of Orladeyo once daily to treat acute exacerbations of HAE due to the risk of QT prolongation.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related hot articles:

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。